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Increased serum p53 antibody levels indicate poor
prognosis in patients with colorectal cancer
U Kressner1, B Glimelius2, R Bergstrom3, L Pahiman1, A Larsson4 and G Lindmark5
Departments of 'Surgery and 2Oncology, University Hospital, Uppsala; 3Department of Statistics, University of Uppsala, Uppsala; 4Department of Clinical
Chemistry, University Hospital, Uppsala; 5Department of Surgery, Umec University Hospital, Umec, Sweden
Summary Serum p53 antibody levels were analysed using an enzyme-linked immunosorbent assay in serum samples obtained before
surgery from 184 consecutive patients with primary colorectal cancer. Possible associations with tumour stage and tumour differentiation and
the relation to patient survival time after a median follow-up of 6 years were studied. Analysis of serum p53 antibodies in the entire material
demonstrated prognostic value in univariate analysis (P= 0.02); a finding that did not remain (P= 0.07) when the Dukes' stage was included
in a multivariate analysis model. When the survival analysis was restricted to the potentially cured patients in Dukes' stages A-C, the serum
p53 antibody levels retained independent prognostic value (P = 0.03). No clear association with tumour differentiation was found. We
conclude that analysis of serum p53 antibodies may be of value for the identification of patients with different prognoses. This may be of
relevance for selection of patients for adjuvant treatment.
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Mutations or other changes in the p53 gene - the most frequent
genetic alterations found in human malignancies (Levine et al,
1991; Harris and Hollstein, 1993) - can be detected in 40-70% of
all colorectal adenocarcinomas (Hollstein et al, 1991; Vogelstein
and Kinzler, 1992; Hamelin et al, 1994; Chang et al, 1995). It has
been reported that p53 mutations are associated with poor prog-
nosis in colorectal cancer (Hamelin et al, 1994; Goh et al, 1995;
Finkelstein et al, 1996; Smith et al, 1997), while such a relation
was not observed by Dix et al (1994a). Overexpression of the p53
protein is detectable in 30-70% of the tumours using immuno-
histochemistry. In some studies (Remvikos et al, 1992; Sun et al,
1992; Auvinen et al, 1994; Bosari et al, 1994) p53 protein over-
expression has been shown to correlate to patient survival, while
this has not been confirmed in other studies (Bell et al, 1993; Baas
et al, 1994; Dix et al, 1994a; Morrin et al, 1994; Mulder et al,
1995; Kressner et al, 1996, Pricolo et al, 1996; Poller et al, 1997).
Mutant p53 protein, and other tumour-specific antigens, may be
a target of the host's immune response (Schlichtholtz et al, 1992;
Mudenda et al, 1994). Studies have shown that 9-26% of patients
with different carcinomas have mounted a humoral immune
response (antibodies) to abnormal p53 protein (Caron de Fromental
et al, 1987; Levine et al, 1991; Angelopoulou et al, 1994). Thus,
anti-p53 antibodies may be a serological marker for malignancy.
Recent studies have shown increased serum antibody levels against
mutant p53 protein in patients with breast (Crawford et al, 1982;
Davidoff et al, 1992; Schlichtholtz et al, 1992; Mudenda et al,
1994), lung (Winter et al, 1992; Schlichtholtz et al, 1994) and
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colorectal cancer (Houbiers et al, 1995; Angelopoulou et al, 1997).
Two of the studies in breast cancer patients have indicated that the
occurrence of p53 antibodies may be a useful determinant with
regard to poor prognosis (Schlichtholtz et al, 1992; Mudenda et al,
1994). This was also seen in the study on patients with colorectal
cancer, but the prognostic information was limited to tumours in
Dukes' stage A and Astler-Coller B1 (Houbiers et al, 1995).
The aim of this study was to evaluate whether the levels ofp53
antibodies in serum samples, obtained before surgery from
patients with colorectal cancer, are ofimportance for prediction of
tumour stage and, thus, of potential value for selecting patients
resected for cure to adjuvant treatment.
MATERIALS AND METHODS
Patients
Serum samples were collected before surgery from 184 patients
resected for colorectal cancer in Uppsala and Falun County during
the years from January 1987 to November 1992. The age and sex
distribution, Dukes' stage and tumour differentiation are given in
Table 1. One hundred and fifty-six patients (85%) were resected
for cure. In the remaining 28 patients, distant metastases were
detected peroperatively, and consequently they underwent a pallia-
tive resection. This group was classified as Dukes' stage D. At
follow-up in October 1995, 82 (45%) patients had died from
cancer or from other causes, but with known tumour burden.
Twenty-eight (15%) patients died from other causes without any
indications of tumour relapse. No patient was lost at follow-up.
The median survival time of the 74 living patients was 80 months
(range 33-102). Routine biopsies from each tumour were taken
for histopathological classification. The tumours were graded
according to the WHO classification (Morson and Sobin, 1976)
and staged according to the Dukes' classification system (Dukes
and Bussey, 1958).
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Table 1 Comparison of patients, age, gender, tumour stage and tumour differentiation in relation to increased serum p53 antibody levels in colorectal cancer
Cases (n) Number of cancer-related deaths P-value
p53 antibody level (n) p53 antibody level
Yes n (°%) No n (%)
Age (all patients) 184 59 (32) 34 (58) 48 (38)
<70 (30-69) 87 26 (30) 16 (62) 22 (36)
>70 (70-89) 97 33 (34) 18 (55) 26 (41) NS
Gender
Female 89 26 (29) 12 (46) 19 (30)
Male 95 33 (35) 22 (67) 29 (47) NS
Dukes' stage
A 31 10 (32) 3 (30) 3 (14)
B 84 26 (31) 12 (46) 15 (26)
C 41 14 (34) 10 (71) 13 (48)
D 28 9 (32) 9 (100) 17 (89) NS
Tumour differentiation
Good 31 9 (29) 6 (67) 5 (23)
Moderate 127 39 (30) 21 (54) 35 (40)
Poor 26 11 (42) 7 (64) 8 (53) NS
Serum samples and ELISA assay for anti-p53
antibodies
The serum samples were stored at -70°C until analysed. The
measurements of anti-p53 were performed using enzyme-linked
immunosorbent assay (ELISA) (Dianova, Hamburg, Germany).
Recombinant p53 protein was coated to a microtitre plate.
Peroxidase-conjugated goat anti-human IgG antibody was added
to patients' sera as secondary antibody. After incubation, the
optical density was determined using spectrophotometry at
450 nm. Positive control sera, containing a constant amount of
anti-p53 antibodies, was obtained from Dianova. All samples were
assayed in duplicate and considered positive at an optical density
above the low positive control sample. We chose a p53 index of
0.01 as cut-off level as this is recommended by the manufacturer
as the 'low control'.
Immunohistochemical analysis of overexpression of
p53 protein
p53 protein overexpression was evaluated using an immunohisto-
chemical method (Kressner et al, 1996). Briefly, DO-7 monoclonal
antibody was used in combination with biotinylated horse anti-
mouse IgG antibody as secondary antibody, followed by
avidin-biotin blocking kit and ethyl carbazole substrate. The
sections were classified as negative or positive.
Statistical analyses
The Cox proportional hazards model was used in both the
univariate and the multivariate survival analyses. Survival curves
were constructed using the Kaplan-Meier method, and differences
between curves were tested using the log-rank test (Peto et al,
1977). The chi-square test was used to test for differences in distri-
bution between groups. P-values of less than 0.05 were considered
statistically significant.
RESULTS
p53 antibodies and tumour stage, tumour
differentiation and p53 immunohistochemistry
Overall, 32% (59 out of 184) ofthe patients had increased levels of
p53 antibodies detected in their serum (Table 1). The range of the
p53 antibody levels was 0.01-2.74. The proportion of p53 posi-
tivity in serum was independent of age, sex, Dukes' stage and
tumour differentiation. There were similar proportions of either
Dukes' stages (A-D) in both the serum-positive and the serum-
negative groups. The levels of serum p53 antibodies increased
with more advanced Dukes' stage, but the increase was not statis-
tically significant (data not shown).
For 110 of the 184 patients, we stained full-cross tumour biopsy
sections immunohistochemically for expression of p53 protein
(wild type/mutated) with the anti-p53 antibody DO-7 (Kressner et
al, 1996). The association of tumours with p53 protein overexpres-
sion with increased serum p53 antibody levels was significant: 24
(45%) of 53 patients with tumours showing overexpression had
high levels of serum p53 antibodies, while this was the case in only
6 (11% I) of 57 patients without p53 overexpression (P = 0.005).
p53 antibodies and prognosis
There was a significant relationship between serum p53 antibody
status and cancer-specific survival time, with shorter survival time
for those patients who had increased levels of p53 serum antibodies
than for those without. This finding was observed both when the
entire patient material was analysed (P = 0.02, log-rank test) and
when the analysis was restricted to the potentially cured patients with
tumours in Dukes' stages A-C (P = 0.03, log-rank test; Figure 1).
An analysis based on all four Dukes' stages, and with p53 anti-
body status categorized as shown in Table 2, showed decreased
survival with increased p53 antibody index in a univariate analysis.
The relative hazards (RHs) were 1.55 (95% CI 0.78-3.07), 1.61
(0.85-3.04) and 1.98 (1.07-3.68). In a multivariate model
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Table 2 Univariate and multivariate analyses showing the effects of serum p53 antibody levels and Dukes' stage on survival in patients resected for colorectal
cancer (Dukes' stages A-C). End point: disease-specific mortality. The multivariate model 1 contains only p53i and Dukes' stage. The multivariate model 2 in
addition contains sex, age, localization, tumour differentiation and serum CEA levels
Univariate Multivariate 1 Multivariate 2
Variable n (dead) RH 95% Cl P RH 95% Cl P RH 95% Cl P
p53
No 106 (31) 1.00 (Ref.) 1.0 (Ref.) 1.0 (Ref.)
Yes (overall) 50 (25) 1.94 1.15-3.30 0.03
p53i
0.01-0.06 16 (7) 1.65 0.73-3.76 0.23 1.72 0.75-3.91 0.20 1.49 0.56-3.95 0.43
>0.06-0.85 18 (9) 1.82 0.86-3.82 0.12 2.03 0.96-4.28 0.06 2.28 1.04-5.01 0.04
>0.85 16 (9) 2.35 1.12-4.96 0.02 2.19 1.04-4.61 0.04 1.99 0.87-4.54 0.10
Dukes' stage
A 33 (4) 1.00 (Ref.) 1.0 (Ref.) 1.0 (Ref.)
B 82 (25) 2.09 0.86-5.07 0.10 2.03 0.84-4.93 0.12 2.89 1.07-7.77 0.04
C 41 (21) 4.16 1.70-10.2 0.002 4.01 1.62-9.92 0.0027 5.65 2.09-15.3 0.001
RH, relative hazard; Cl, confidence interval; p53i, p53 index.
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Figure 1 (A) Life-table plots for all 184 patients (Dukes' stages A-D) and
(B) the 156 patients operated for cure (Dukes' stages A-C). Group 1,
patients with increased levels of serum p53 antibodies; group 2, patients
without increased levels of serum p53 antibodies. -, p53(+); - - -, p53(-). 0,
complete responses (i.e. patients who have died from cancer); +, censored
responses (i.e. patients who are alive or who have died from causes other
than cancer)
adjusting for Dukes' stage, the significant effect of serum p53
levels disappeared, although the tendency that p53 antibody status
was a risk factor remained (P = 0.07). The RHs were 1.77
(0.89-3.53), 1.74 (0.92-3.31) and 1.32 (0.70-2.49).
In the group of potentially cured patients, the prognostic value
of p53 antibody status remained, however, even after adjustment
for Dukes' stage (Table 2). The RH in the highest category was 2.2
(1.04-4.61). Further adjustments for a large number of variables
had only marginal effects as regards the effect of p53. The RHs in
the two highest categories remained at about 2, with P-values
equal to 0.04 and 0.10.
DISCUSSION
The proportion of patients with detectable serum p53 antibodies
(32%) is consistent with a previous report on colorectal cancer
(Houbiers et al, 1995), but represents a higher figure than that
reported by Angelopoulou et al (1994) who found p53 antibodies
in 16% oftheir patients.
We found that the p53 antibody status was not only a prognostic
indicator in a univariate analysis but also an independent prog-
nostic factor when analysed in a multivariate model regarding the
subset ofpatients who were radically resected. The result is thus in
contrast to Houbiers et al (1995), who did not find an independent
relation with prognosis in a multivariate analysis including the
Dukes' stage but reported a weak association (P = 0.04) between
high p53 serum levels and prognosis in patients with an early stage
of the disease (Dukes' stage A).
Thus, detectable levels ofp53 antibodies in serum seem to indi-
cate more aggressive tumours in colorectal cancer. Studies in other
tumour types support this notion (Crawford et al, 1982; Davidoffet
al, 1992; Schlichtholtz et al, 1992; Winter et al, 1992; Mudenda et
al, 1994). Loss of thep53 gene suppressor function has previously
been reported in a range of human malignancies (Hollstein et al,
1991; Levine et al, 1991; Chang et al, 1995), including colorectal
cancer (Levine et al, 1991; Remvikos et al, 1992; Sun et al, 1992;
Vogelstein and Kinzler, 1992; Bell et al, 1993; Auvinen et al, 1994;
Bosari et al, 1994; Dix et al, 1994a; Hamelin et al, 1994; Goh et al,
1995). A mutation in the p53 gene results in an accumulation of
mutant p53 protein or in an overproduction of normal wild-type
p53 protein (Dix et al, 1994a and b). Mutant p53 protein is more
stable than the wild-type p53 protein (Bruner et al, 1993; Dix et al,
1994a and b), and this seems to be necessary for the development
of a humoral response with detectable levels ofanti-p53 antibodies
in the peripheral circulation (Crawford et al, 1982).
In this study, and in concordance with Houbiers et al (1995), we
were also able to demonstrate a significant association between
overexpression ofp53 in tumour sections with expression ofserum
p53 antibodies (P < 0.005), although increased levels were only
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seen in 45% of the patients with positive immunohistochemistry.
This implies that either the cut-off level is too high or that the
development of antibodies is dependent upon the type of genetic
change underlying the overexpression of p53 protein required for
positive immunohistochemistry. Another point is that a p53 muta-
tion does not always result in immunohistochemical detection of
overexpression of p53 protein (Dix et al, 1994a; Houbiers et al,
1995; Kressner et al, manuscript submitted)
Preoperatively increased serum tumour levels ofCEA, TPA and
other markers have been reported to provide prognostic informa-
tion, but their clinical relevance is yet to be defined as they mainly
identify patients with metastases already detectable at diagnosis
(Lindmark et al, 1995). Post-operatively, they may also provide
additional prognostic information to that given by Dukes' stage,
but the associations are then weaker, and thus the clinical rele-
vance is also doubtful. In the present study, a significant effect of
serum levels ofp53 remained after adjustment for the preoperative
level of serum CEA. The prognostic effect of CEA was, in this
patient material, rather strong, although it did not retain its prog-
nostic information in either of the multivariate models shown in
Table 2 (data not shown).
If the presence of serum p53 antibodies, available before
surgery, is a marker ofpoorprognosis, which our study suggests, it
could be of value preoperatively for the selection of patients with
colorectal cancer for additional treatment. It may also be useful in
post-operative patient monitoring. This application has to be
explored in further studies.
ACKNOWLEDGEMENTS
This study was supported by grants from the Swedish Cancer
Society (1921-B94-12XCC), Swedish Research Council (project
9875) and the University Hospital Cancer Foundation, Uppsala.
REFERENCES
Angelopoulou K, Diamandis EP, Sutherland DJA, Kellen JA and Bunting PS (1994)
Prevalence of serum antibodies against the p53 tumor suppressor gene protein
in various cancers. Int J Cancer 58: 480-487
Angelopoulou K, Stratis M and Diamandis EP (1997) Humoral immune response
against p53 protein in patients with colorectal carcinoma. Int J Cancer 70:
46-51
Auvinen A, Isola J, Visakorpi T, Virtanen S and Hakama M (1994) Overexpression
ofp53 and long-term survival in colon carcinoma. BrJ Cancer 70: 293-296
Baas 10, Mulder JWR, Offerhaus GJ, Vogelstein B and Hamilton SR (1994) An
evaluation of six antibodies for immunohistochemistry of mutant p53 gene
product in archival colorectal neoplasms. JPathol 72: 5-12
Bell SM, Scott N, Cross D, Sagar P, Lewis FA, Blair E, Taylor G, Dixon M and
Quirke P (1993) Prognostic value ofp53 overexpression and c-Ki-ras gene
mutations in colorectal cancer. Gastroenterology 104: 57-64
Bosari S, Giuseppe V, Bossi P, Maggioni M, Coggi G, Murray J and Lee A (1994)
Cytoplasmatic accumulation ofp53 protein: an independent prognostic
indicator in colorectal adenocarcinoma. JNatl CancerInst 86: 681-687
Bruner JM, Connely JH and Saya H (1993) p53 protein immunostaining in routinely
processed paraffin-embedded sections. Mod Pathol 6: 189-194
Caron de Fromentel C, May-Levin F, Mouriesse H, Lemerle J, Chandrasekaran K
and May P (1987) Presence ofcirculating antibodies against cellular protein
p53 in notable proportion ofchildren with B-cells lymphoma. Int J Cancer 39:
185-189
Chang F, Syrjanen S and Syrjanen K (1995) Implications ofthe p53 tumour-
suppressor gene in clinical oncology. J Clin Oncol 4: 1009-1022
Crawford LV, Pim DC and Bulbrook RD (1982) Detection ofantibodies against the
cellular protein p53 in the sera from patients with breast cancer. Int J Cancer
30: 403-408
Davidoff AM, Iglehart JD and Marks JR (1992) Immune response to p53 is
dependent upon p53/HSP70 complexes in breast cancers. Proc NatlAcad Sci
USA 89: 3439-3442
Dix B, Robbins P, Soong R, Jenner D, House A and lacopetta B (1994a) The
common molecular genetic alterations in Dukes B and C colorectal carcinomas
are not short-term prognostic indicators of survival. IntJ Cancer59: 747-751
Dix B, Robbins P, Carello A, House A and lacopetta B (1994b) Comparison ofp53
gene mutation and protein overexpression in colorectal carcinoma. BrJ Cancer
70: 585-590
Dukes CE and Bussey HJR (1958) The spread ofrectal cancer and its effect on
prognosis. BrJ Cancer 12: 309-320
Finkelstein SD, Przygodszki R, Pricolo VE, Sakallah SA, Swalsky PA, Bakker A,
Lanning R, Bland KI and Cooper DL (1996) Prediction ofbiologic
aggressiveness in colorectal cancer by p53/K-ras-2 topographic genotyping.
Molec Diagn 1: 5-28
Goh H S, Yao J and Smith DR (1995) p53 point mutation and survival in colorectal
cancer patients. CancerRes 55: 5217-5222
Hamelin R, Laurent-Puig GP, Olschwang S, Jego N, Asselain B, Remvikos Y,
Girodet J, Salmon RJ and Thomas G (1994) Association ofp53 mutations with
short survival in colorectal cancer. Gastroenterology 106: 42-48
Harris CC and Hollstein M (1993) Clinical implications ofthe p53 tumour-
suppressor gene. NEngl JMed 329: 1318-1327
Hollstein M, Sidransky D, Vogelstein B and Harris CC (1991) P53 mutations in
human cancers. Science 253: 49-53
Houbiers JG, Van Der Burg SH, Van de Watering LM, Tollenaar RA, Brand A,
Van de Velde CJ and MeliefCJ (1995) Antibodies against p53 are associated
with poor prognosis ofcolorectal cancer. BrJ Cancer 72: 637-641
Kressner U, Lindmark G, Gerdin B, Pahlman L and Glimelius B (1996)
Immunohistochemical p53 staining is of limited value in the staging and
prognostic prediction ofcolorectal cancer. Anticancer Res 16: 951-958
Levine AJ, Momand J and Finlay CA (1991) The p53 tumour suppressor gene.
Nature 351: 453-456
Lindmark G, Bergstrom R, Pahlman L and Glimelius B (1995) The association of
preoperative serum markers with Dukes stage and survival in colorectal cancer.
BrJ Cancer 71: 1090-1094
Morrin M, Kelly M, Barret N and Delaney P (1994) Mutations of Ki-ras and p53
genes in colorectal cancer and their prognostic significance. Gut 35: 1627-1631
Morson B and Sobin L (1976) Histological Typing ofIntestinal Tumors.
International Histological Classification ofTumours, No. 15, WHO:
Geneva
Mudenda B, Green JA, Green B, Jenkins JR, Robertson L, Tarunina M and Leinster
SJ (1994) The relationship between serum p53 autoantibodies and
characteristics ofhuman breast cancer. BrJ Cancer 69: 1115-1119
Mulder JWR, Bass 10, Polak MM, Goodman SN and Offerhaus GIA (1995)
Evaluation ofp53 protein expression as a marker for long term prognosis in
colorectal carcinoma. BrJ Cancer 71: 1257-1262
Peto R, Pike M, Armitage P, Breslow N, Cox D, Howard S, Mantel N, McPherson
K, Peto J and Smith P (1977) Design and analysis ofrandomized clinical trials
requiring prolonged observations ofeach patient. II. Analysis and examples.
BrJSurg 35: 1-39
Poller DN, Baxter KJ and Shepherd NA (1997) p53 and Rbl protein expression: are
they prognostically useful in colorectal cancer? BrJ Cancer 75: 87-93
Pricolo VE, Finkelstein SD, Wu TT, Keller G, Bakker A, Svalsky PA and Bland KI
(1996) Prognostic value ofTP53 and K-ras-2 mutational analysis in stage III
carcinoma ofthe colon. Am JSurg 171: 41-46
Remvikos Y, Tominaga 0, Hammel P, Laurent-Puig P, Salmon RJ, Dutrillaux B and
Thomas G (1992) Increased p53 protein content ofcolorectal tumours
correlates with poor survival. BrJ Cancer 66: 758-764
Schlichtholtz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calyo I and
Soussi T (1992) The immune reponse to p53 in breast cancer patients is
directed against immunodominant epitopes unrelated to the mutational hot spot.
Cancer Res 52: 6380-6384
Schlichtholtz B, Tredaniel J, Lubin R, Zalcman G, Hirsch A and Soussi T (1994)
Analyses ofp53 antibodies in sera ofpatients with lung carcinoma define
immunodominant regions in the p53 protein. BrJ Cancer 69: 809-816
Smith DR, Ji CY, and Goh HS (1997) Prognostic significance ofp53
overexpression and mutation in colorectal adenocarcinomas. BrJ Cancer
74: 216-233
Sun XF, Carstensen JM, Zhang H, Stal 0, Wingren S, Hatschek T and Nordenskjold
B (1992) Prognostic significance ofcytoplasmic p53 oncoprotein in colorectal
adenocarcinoma. Lancet 340: 1369-1373
Vogelstein B and Kinzler KW (1992) P53 function and dysfunction. Cell 70:
523-526
Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF and Carbone DP (1992)
Development ofantibodies against p53 in lung cancer patients appears to be
dependent on the type ofp53 mutation. Cancer Res 52: 4168-4174
C Cancer Research Campaign 1998 British Journal ofCancer (1998) 77(11), 1848-1851